

Mark C Gillies, Franzco

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1715332/mark-c-gillies-franzco-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115
papers

3,635
citations

30
h-index

58
g-index

133
ext. papers

4,594
ext. citations

4.9
avg, IF

5.27
L-index

#	Paper	IF	Citations
115	Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry.. <i>Ophthalmology and Therapy</i> , 2022 , 11, 797	5	0
114	Metabolism Dysregulation in Retinal Diseases and Related Therapies. <i>Antioxidants</i> , 2022 , 11, 942	7.1	2
113	Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands. <i>Acta Ophthalmologica</i> , 2021 , 99, e884-e892	3.7	4
112	Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis. <i>Translational Vision Science and Technology</i> , 2021 , 10, 5	3.3	0
111	Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry. <i>BMJ Open Ophthalmology</i> , 2021 , 6, e000903	3.2	1
110	FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project. <i>Retina</i> , 2021 , 41, 118-124	3.6	5
109	ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR. <i>Retina</i> , 2021 , 41, 1446-1454	3.6	3
108	Effect of selectively knocking down key metabolic genes in Müller glia on photoreceptor health. <i>Glia</i> , 2021 , 69, 1966-1986	9	5
107	Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 652-663	2.4	3
106	Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 570-578	2.4	1
105	Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2021 , 259, 1463-1470	3.8	4
104	Inhibition of Mitochondrial Respiration Impairs Nutrient Consumption and Metabolite Transport in Human Retinal Pigment Epithelium. <i>Journal of Proteome Research</i> , 2021 , 20, 909-922	5.6	1
103	Vitreoretinal Society of India practice pattern survey 2020: Medical retina. <i>Indian Journal of Ophthalmology</i> , 2021 , 69, 1430-1439	1.6	2
102	Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. <i>British Journal of Ophthalmology</i> , 2021 ,	5.5	1
101	Outer Retinal Layer Thickening Predicts the Onset of Exudative Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2021 , 231, 19-27	4.9	2
100	PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020 , 40, 2285-2295	3.6	9
99	Metabolic Features of Mouse and Human Retinas: Rods versus Cones, Macula versus Periphery, Retina versus RPE. <i>IScience</i> , 2020 , 23, 101672	6.1	10

98	Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 802-812	2.4	2
97	Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 946-955	2.4	1
96	Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 636-643	2.4	15
95	Outcomes of cataract surgery in eyes with diabetic macular oedema: Data from the Fight Retinal Blindness! Registry. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 462-469	2.4	2
94	Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry. <i>Ophthalmology</i> , 2020 , 127, 369-376	7.3	9
93	SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020 , 40, 1696-1703 ^{3.6}	3.6	2
92	Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. <i>Ophthalmology</i> , 2020 , 127, 608-615	7.3	17
91	ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2020 , 40, 866-872	3.6	3
90	Local delivery of corticosteroids in clinical ophthalmology: A review. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 366-401	2.4	18
89	Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. <i>British Journal of Ophthalmology</i> , 2020 , 104, 1064-1069	5.5	3
88	Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2020 , 138, 1234-1240	3.9	3
87	Selective knockdown of hexokinase 2 in rods leads to age-related photoreceptor degeneration and retinal metabolic remodeling. <i>Cell Death and Disease</i> , 2020 , 11, 885	9.8	9
86	Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry. <i>Ophthalmology Retina</i> , 2020 , 4, 861-870	3.8	3
85	Preclinical and clinical studies of photobiomodulation therapy for macular oedema. <i>Diabetologia</i> , 2020 , 63, 1900-1915	10.3	5
84	Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration: The RAMPS Study. <i>Ophthalmology Retina</i> , 2020 , 4, 871-880	3.8	9
83	Targeting the Notch and TGF- β -signaling pathways to prevent retinal fibrosis and. <i>Theranostics</i> , 2020 , 10, 7956-7973	12.1	15
82	Adherence to eye examination guidelines among individuals with diabetes: An analysis of linked health data. <i>Clinical and Experimental Ophthalmology</i> , 2020 , 48, 1229-1238	2.4	5
81	Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). <i>Ophthalmology</i> , 2020 , 127, 198-210	7.3	14

80	Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. <i>American Journal of Ophthalmology</i> , 2020 , 210, 116-124	4.9	31
79	Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. <i>British Journal of Ophthalmology</i> , 2020 , 104, 1052-1056	5.5	9
78	MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus 2019 , 60, 3937-3942		9
77	Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample. <i>Scientific Reports</i> , 2019 , 9, 612	4.9	0
76	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. <i>JAMA Ophthalmology</i> , 2019 , 137, 372-379	3.9	59
75	Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. <i>Ophthalmology</i> , 2019 , 126, 801-810	7.3	26
74	Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. <i>American Journal of Ophthalmology</i> , 2019 , 204, 105-112	4.9	10
73	Development of New Proliferative Diabetic Retinopathy in the BEVORDEX Trial. <i>Ophthalmology Retina</i> , 2019 , 3, 286-287	3.8	2
72	ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. <i>Genetics in Medicine</i> , 2019 , 21, 2103-2115	8.1	7
71	A single-cell transcriptome atlas of the adult human retina. <i>EMBO Journal</i> , 2019 , 38, e100811	13	92
70	Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. <i>Ophthalmology Retina</i> , 2019 , 3, 623-628	3.8	14
69	Human macular Müller cells rely more on serine biosynthesis to combat oxidative stress than those from the periphery. <i>ELife</i> , 2019 , 8,	8.9	18
68	Differentiation of Retinal Glial Cells From Human Embryonic Stem Cells by Promoting the Notch Signaling Pathway. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 527	6.1	7
67	Optogenetic approaches to vision restoration. <i>Experimental Eye Research</i> , 2019 , 178, 15-26	3.7	53
66	Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. <i>Ophthalmology</i> , 2019 , 126, 723-734	7.3	116
65	Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents. <i>Ophthalmology</i> , 2019 , 126, 735-742	7.3	20
64	Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. <i>British Journal of Ophthalmology</i> , 2019 , 103, 1158-1162	5.5	1
63	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2019 , 126, 64-74	7.3	15

62	Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. <i>Survey of Ophthalmology</i> , 2018 , 63, 638-645	6.1	29
61	Normative Data for Retinal-Layer Thickness Maps Generated by Spectral-Domain OCT in a White Population. <i>Ophthalmology Retina</i> , 2018 , 2, 808-815.e1	3.8	25
60	Outcomes in Neovascular Age-Related Macular Degeneration when Neovascular Lesion Activity Is Uncertain: Observational Study. <i>Ophthalmology Retina</i> , 2018 , 2, 531-538	3.8	1
59	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018 , 65, 127-146	20.5	128
58	Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. <i>American Journal of Ophthalmology</i> , 2018 , 190, 50-57	4.9	11
57	TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2018 , 38, 20-28	3.6	58
56	The Interval between Treatments of Bevacizumab and Dexamethasone Implants for Diabetic Macular Edema Increased over Time in the BEVORDEX Trial. <i>Ophthalmology Retina</i> , 2018 , 2, 231-234	3.8	6
55	Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. <i>Clinical and Experimental Ophthalmology</i> , 2018 , 46, 266-274	2.4	3
54	A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2018 , 256, 1839-1846	3.8	8
53	Choroidal Structural Changes Correlate With Neovascular Activity in Neovascular Age Related Macular Degeneration 2018 , 59, 3836-3841		25
52	Identification of novel diabetes impaired miRNA-transcription factor co-regulatory networks in bone marrow-derived Lin ⁻ /VEGF-R2 ⁺ endothelial progenitor cells. <i>PLoS ONE</i> , 2018 , 13, e0200194	3.7	4
51	Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. <i>BMC Medical Genetics</i> , 2018 , 19, 71	2.1	32
50	Retinal pigment epithelium in the pathogenesis of age-related macular degeneration and photobiomodulation as a potential therapy?. <i>Clinical and Experimental Ophthalmology</i> , 2018 , 46, 670-686	2.4	47
49	Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2018 , 102, 479-482	5.5	8
48	RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study. <i>Retina</i> , 2018 , 38, 1954-1961	3.6	4
47	Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018 , 125, 66-74	7.3	49
46	A Combination Therapy Targeting Endoglin and VEGF-A Prevents Subretinal Fibro-Neovascularization Caused by Induced Müller Cell Disruption 2018 , 59, 6075-6088		9
45	The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15

44	Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies. <i>Journal of Ophthalmology</i> , 2018 , 2018, 3640135	2	2
43	Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2017 , 101, 1329-1333	5.5	7
42	Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761). <i>Ophthalmology</i> , 2017 , 124, e31-e32	7.3	14
41	Seven-year Trends in Visual Acuity at First Presentation in Patients with Neovascular AMD. <i>Ophthalmology</i> , 2017 , 124, 270-272	7.3	4
40	Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016 , 123, 2393-2400	7.3	31
39	Differential expression of microRNAs in retinal vasculopathy caused by selective Müller cell disruption. <i>Scientific Reports</i> , 2016 , 6, 28993	4.9	15
38	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2016 , 168, 1-12	4.9	73
37	Reply. <i>Journal of AAPOS</i> , 2016 , 20, 187-8	1.3	
36	Promoter polymorphism at the tumour necrosis factor/lymphotoxin-alpha locus is associated with type of diabetes but not with susceptibility to sight-threatening diabetic retinopathy. <i>Diabetes and Vascular Disease Research</i> , 2016 , 13, 164-7	3.3	3
35	A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. <i>Acta Diabetologica</i> , 2016 , 53, 643-50	3.9	49
34	Bevacizumab or Dexamethasone Implants for DME: 2-year Results (The BEVORDEX Study). <i>Ophthalmology</i> , 2016 , 123, 1399-401	7.3	44
33	Vision-Related Quality of Life Outcomes in the BEVORDEX Study: A Clinical Trial Comparing Ozurdex Sustained Release Dexamethasone Intravitreal Implant and Bevacizumab Treatment for Diabetic Macular Edema 2016 , 57, 5541-5546		26
32	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1640-1645	5.5	30
31	Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1000-1004	5.5	24
30	METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016 , 36, 1418-31	3.6	104
29	Effectiveness and Safety of an Intracameral Injection of Cefuroxime for the Prevention of Endophthalmitis After Cataract Surgery With or Without Perioperative Capsular Rupture. <i>JAMA Ophthalmology</i> , 2016 , 134, 810-6	3.9	50
28	Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. <i>Ophthalmology</i> , 2016 , 123, 2545-2553	7.3	49
27	Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. <i>Ophthalmology</i> , 2015 , 122, 1837-45	7.3	152

26	Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema. <i>Ophthalmology</i> , 2015 , 122, 1828-36	7.3	18
25	Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. <i>British Journal of Ophthalmology</i> , 2015 , 99, 359-64	5.5	13
24	Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. <i>Diabetologia</i> , 2015 , 58, 2288-97	10.3	60
23	Patient experiences in retinal trials: a cross-sectional study. <i>BMC Ophthalmology</i> , 2015 , 15, 80	2.3	8
22	Central retinal vein occlusion in an otherwise healthy child treated successfully with a single injection of bevacizumab. <i>Journal of AAPOS</i> , 2015 , 19, 473-4	1.3	3
21	Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2015 , 122, 1212-9	7.3	116
20	Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. <i>Ophthalmology</i> , 2015 , 122, 589-594.e1	7.3	20
19	Profiling of microRNAs involved in retinal degeneration caused by selective Müller cell ablation. <i>PLoS ONE</i> , 2015 , 10, e0118949	3.7	26
18	A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. <i>Ophthalmology</i> , 2014 , 121, 2473-81	7.3	210
17	Intravitreal therapy in bilateral neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2014 , 121, 2073-4	7.3	12
16	Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. <i>Retina</i> , 2014 , 34, 188-95	3.6	74
15	Reporting of harms by randomised controlled trials in ophthalmology. <i>British Journal of Ophthalmology</i> , 2014 , 98, 1003-8	5.5	4
14	The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2014 , 121, 1246-51	7.3	39
13	Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. <i>Ophthalmology</i> , 2014 , 121, 676-81	7.3	36
12	Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes 2013 , 54, 5754-60		29
11	Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial 2010 , 51, 2322-8		12
10	Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial. <i>Clinical and Experimental Ophthalmology</i> , 2010 , 38, 605-12	2.4	22
9	Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. <i>Ophthalmology</i> , 2009 , 116, 2182-7	7.3	77

8	Familial asymptomatic macular telangiectasia type 2. <i>Ophthalmology</i> , 2009 , 116, 2422-9	7.3	60
7	Circulating antiretinal autoantibodies and age-related macular degeneration: what is the link?. <i>Expert Review of Ophthalmology</i> , 2007 , 2, 27-31	1.5	
6	Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2007 , 91, 1323-6	5.5	21
5	The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. <i>American Journal of Ophthalmology</i> , 2007 , 144, 134-6	4.9	11
4	Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. <i>Ophthalmology</i> , 2006 , 113, 1533-8	7.3	353
3	Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. <i>JAMA Ophthalmology</i> , 2004 , 122, 336-40		268
2	A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. <i>JAMA Ophthalmology</i> , 2003 , 121, 667-73		307
1	A randomized phase II trial of interferon-alpha2b versus 5-fluorouracil after trabeculectomy. <i>Australian and New Zealand Journal of Ophthalmology</i> , 1999 , 27, 37-44		17